127 related articles for article (PubMed ID: 20034363)
1. Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes - an update.
Fischer B; Elias D; Bretzel RG; Linn T
Expert Opin Biol Ther; 2010 Feb; 10(2):265-72. PubMed ID: 20034363
[TBL] [Abstract][Full Text] [Related]
2. DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes.
Tuccinardi D; Fioriti E; Manfrini S; D'Amico E; Pozzilli P
Expert Opin Biol Ther; 2011 Sep; 11(9):1233-40. PubMed ID: 21751937
[TBL] [Abstract][Full Text] [Related]
3. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results.
Eldor R; Kassem S; Raz I
Diabetes Metab Res Rev; 2009 May; 25(4):316-20. PubMed ID: 19267355
[TBL] [Abstract][Full Text] [Related]
4. DiaPep277 (DeveloGen).
Giannoukakis N
Curr Opin Investig Drugs; 2005 Oct; 6(10):1043-50. PubMed ID: 16259226
[TBL] [Abstract][Full Text] [Related]
5. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.
Raz I; Elias D; Avron A; Tamir M; Metzger M; Cohen IR
Lancet; 2001 Nov; 358(9295):1749-53. PubMed ID: 11734230
[TBL] [Abstract][Full Text] [Related]
6. Immuno-intervention and preservation of beta-cell function in type 1 diabetes.
Pozzilli P
Diabetes Metab Res Rev; 2007 May; 23(4):255-6. PubMed ID: 17476663
[No Abstract] [Full Text] [Related]
7. Clinical update on the use of immuno modulators (antiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes.
Pozzilli P; Guglielmi C; Maggi D; Carlone A; Buzzetti R; Manfrini S
Curr Pharm Des; 2011; 17(29):3224-8. PubMed ID: 21864261
[TBL] [Abstract][Full Text] [Related]
8. DiaPep277® and immune intervention for treatment of type 1 diabetes.
Schloot NC; Cohen IR
Clin Immunol; 2013 Dec; 149(3):307-16. PubMed ID: 24090708
[TBL] [Abstract][Full Text] [Related]
9. [Immunological intervention to preserve beta-cell function in type 1 diabetes].
Schloot NC
Dtsch Med Wochenschr; 2010 May; 135(18):915-21. PubMed ID: 20425677
[TBL] [Abstract][Full Text] [Related]
10. Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitus.
Eldor R; Cohen IR; Raz I
Int Rev Immunol; 2005; 24(5-6):327-39. PubMed ID: 16318985
[TBL] [Abstract][Full Text] [Related]
11. C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study.
Buzzetti R; Cernea S; Petrone A; Capizzi M; Spoletini M; Zampetti S; Guglielmi C; Venditti C; Pozzilli P;
Diabetes; 2011 Nov; 60(11):3067-72. PubMed ID: 21896927
[TBL] [Abstract][Full Text] [Related]
12. The anti-interleukin-1 in type 1 diabetes action trial--background and rationale.
Pickersgill LM; Mandrup-Poulsen TR
Diabetes Metab Res Rev; 2009 May; 25(4):321-4. PubMed ID: 19405081
[TBL] [Abstract][Full Text] [Related]
13. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.
Schloot NC; Meierhoff G; Lengyel C; Vándorfi G; Takács J; Pánczél P; Barkai L; Madácsy L; Oroszlán T; Kovács P; Sütö G; Battelino T; Hosszufalusi N; Jermendy G
Diabetes Metab Res Rev; 2007 May; 23(4):276-85. PubMed ID: 17103487
[TBL] [Abstract][Full Text] [Related]
14. NOD mouse diabetes: the ubiquitous mouse hsp60 is a beta-cell target antigen of autoimmune T cells.
Birk OS; Elias D; Weiss AS; Rosen A; van-der Zee R; Walker MD; Cohen IR
J Autoimmun; 1996 Apr; 9(2):159-66. PubMed ID: 8738959
[TBL] [Abstract][Full Text] [Related]
15. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.
Raz I; Avron A; Tamir M; Metzger M; Symer L; Eldor R; Cohen IR; Elias D
Diabetes Metab Res Rev; 2007 May; 23(4):292-8. PubMed ID: 17124720
[TBL] [Abstract][Full Text] [Related]
16. [Heat shock protein protects beta cells. Is it possible soon to vaccinate against diabetes?].
MMW Fortschr Med; 2003 May; 145(22):53. PubMed ID: 12866282
[No Abstract] [Full Text] [Related]
17. Rituximab, B-lymphocyte depletion, and beta-cell function.
Nagafuchi S; Katsuta H; Anzai K
N Engl J Med; 2010 Feb; 362(8):761; author reply 761. PubMed ID: 20181981
[No Abstract] [Full Text] [Related]
18. Therapy with GAD in diabetes.
Ludvigsson J
Diabetes Metab Res Rev; 2009 May; 25(4):307-15. PubMed ID: 19267332
[TBL] [Abstract][Full Text] [Related]
19. [The role of hsp60 and hsp70 kDa heat shock protein families in different types of diabetes mellitus].
Korányi L; Hegedüs E; Péterfal E; Kurucz I
Orv Hetil; 2004 Feb; 145(9):467-72. PubMed ID: 15077478
[TBL] [Abstract][Full Text] [Related]
20. Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces Th2-type antibodies.
Bockova J; Elias D; Cohen IR
J Autoimmun; 1997 Aug; 10(4):323-9. PubMed ID: 9237795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
